We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+13.66%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$180M
AUM Growth
+$17.3M
Cap. Flow
-$1.67M
Cap. Flow %
-0.93%
Top 10 Hldgs %
91.75%
Holding
43
New
2
Increased
6
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
WKHS icon
Workhorse Group
WKHS
+$801K
2
CLVS
Clovis Oncology, Inc.
CLVS
+$608K
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$456K
4
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$242K
5
AXDX
Accelerate Diagnostics
AXDX
+$183K

Top Sells

Rank Stock Value
1
MASI
Masimo
MASI
+$1.78M
2
CELG
Celgene Corp
CELG
+$1.2M
3
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$316K
4
ARAY icon
Accuray
ARAY
+$287K
5
CHRS icon
Coherus Oncology
CHRS
+$211K

Sector Composition

Rank Sector Weight
1 Healthcare 95.81%
2 Energy 2.89%
3 Consumer Staples 0.45%
4 Consumer Discretionary 0.38%
5 Industrials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SITO
26
DELISTED
SITO MOBILE, LTD
SITO
$360K 0.2%
140,000
– –
OMED
27
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$319K 0.18%
34,689
-36,000
-51% -$316K
ALDR
28
DELISTED
Alder Biopharmaceuticals
ALDR
$315K 0.18%
15,150
– –
CELGZ
29
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$315K 0.18%
291,877
– –
XNCR icon
30
Xencor
XNCR
$1.48B
$294K 0.16%
12,300
– –
ADXS
31
DELISTED
Advaxis Inc
ADXS
$291K 0.16%
2,373
– –
AAAP
32
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$279K 0.16%
+7,000
New +$242K
BIIB icon
33
Biogen
BIIB
$29.8B
$273K 0.15%
1,000
– –
GNCA
34
DELISTED
Genocea Biosciences, Inc.
GNCA
$238K 0.13%
4,875
– –
PRTK
35
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$215K 0.12%
11,150
– –
OPK icon
36
Opko Health
OPK
$899M
$193K 0.11%
24,158
– –
ARAY icon
37
Accuray
ARAY
$27.9M
$191K 0.11%
40,300
-55,000
-58% -$287K
ROKA
38
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$166K 0.09%
46,731
– –
PACB icon
39
Pacific Biosciences
PACB
$426M
$140K 0.08%
27,000
– –
MACK
40
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$136K 0.08%
5,592
– –
GNMX
41
DELISTED
Aevi Genomic Medicine Inc
GNMX
$126K 0.07%
68,000
+20,000
+42% +$90.5K
CERS icon
42
Cerus
CERS
$581M
– –
-26,500
Closed -$115K
CHRS icon
43
Coherus Oncology
CHRS
$219M
– –
-7,500
Closed -$211K
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return
AF
Align Financial Hermantown, Minnesota $176M AUM
OA
Oceanside Advisors Mount Pleasant, South Carolina $175M AUM 17.96% 1-Year Est. Return

Birchview Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Birchview Capital held 43 positions worth $180M, up 11% from $163M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Birchview Capital's Q1 2017 filing shows 2 new, 6 increased, 6 reduced and 2 closed positions. Its largest new stake was Clovis Oncology, Inc.: 10,000 shares worth $637K. The largest sale was Masimo, an estimated $1.78M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q1 2017 buy was Clovis Oncology, Inc.: 10,000 shares worth $637K.
  • Birchview Capital added most to Workhorse Group in Q1 2017, an estimated $801K increase.
  • Birchview Capital's biggest Q1 2017 reduction was Masimo, cutting an estimated $1.78M.
  • Birchview Capital fully exited Coherus Oncology in Q1 2017, selling an estimated $211K.
  • Birchview Capital's ten largest holdings make up 92% of its $180M portfolio in Q1 2017.
  • Birchview Capital opened 2 new positions and closed 2 in Q1 2017.
  • Birchview Capital's portfolio value rose 11% quarter-over-quarter to $180M.

Based on Birchview Capital's 13F filing for Q1 2017, filed 4 May 2017.